InhaleRx Secures Ethics Approval for Redesigned Trial of Inhaled Therapy Product
MT Newswires Live
Jun 04
InhaleRx (ASX:IRX) secured Human Research Ethics Committee approval for its redesigned IRX-211 phase two clinical trial, which includes an expanded scope, according to a Tuesday filing with the Australian bourse.
The redesigned study increased the sample size to 156 participants, with a target of 78 to complete, the filing said.
IRX-211 is an inhaled therapy being developed for potentially treating cancer pain in opioid-tolerant patients.
Patient dosing is anticipated to start in the third quarter of the year, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.